Hodgkins Lymphoma Clinical Trial
Official title:
A Multicenter Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation Followed by Adoptive Cellular Immunotherapy With Donor Derived Latent Membrane Protein (LMP) Specific-CTLs in Patients With Epstein-Barr Virus (EBV)Positive Refractory or Recurrent Hodgkin Lymphoma
The investigators intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from EBV positive HLA matched sibling or unrelated adult donor combined with post AlloSCT allogeneic donor derived LMP specific cytotoxic T-lymphocyte (CTL) infusions in EBV positive patients with poor risk Hodgkin Lymphoma. One of three reduced intensity conditioning regimens predetermined at each institutional center of the Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) will be utilized for related or matched unrelated adult donor allogeneic transplant followed by donor LMP specific CTL infusion for three doses post AlloSCT. The investigators hypothesize that the addition of donor derived LMP specific CTLs will be safe and feasible.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00383097 -
Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT01517581 -
Brown Fat Activity and White Fat Accumulation
|
N/A | |
Completed |
NCT00515554 -
HD18 for Advanced Stages in Hodgkins Lymphoma
|
Phase 3 | |
Terminated |
NCT01326728 -
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
|
||
Completed |
NCT00837200 -
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
|
Phase 2 | |
Terminated |
NCT02603419 -
Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)
|
Phase 1 | |
Active, not recruiting |
NCT02099266 -
Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment
|
N/A | |
Completed |
NCT02057445 -
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
|
Phase 1 | |
Terminated |
NCT01300611 -
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation
|
Phase 1 | |
Completed |
NCT01014507 -
Protection of Ovarian Function in Female Patients With Hodgkin Lymphoma
|
Phase 2 | |
Enrolling by invitation |
NCT00923442 -
Biology Studies of Hematologic Cancers
|
||
Terminated |
NCT00973804 -
Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders
|
Phase 1 | |
Completed |
NCT00739141 -
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.
|
Phase 2 | |
Recruiting |
NCT05134740 -
(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
|
Phase 1 | |
Completed |
NCT01572662 -
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
|
Phase 2 |